Lobbying disclosures · Lobbying report
PG: second_quarter 2026 lobbying report
-Issues related to FDA review of active ingredients in over-the-counter products -Issues related to Generally Recognized as Safe (GRAS) and Additive Ingredients Regulation -H.R. 1219, Oral Health Products Inclusion Act -Issues related to New Approach Methodologies (NAMs) non-animal technologies used to evaluate drug safety and efficacy -Section 232 Steel/Aluminum Trade Investigation -Issues Related to the Review of the US-Mexico-Canada Trade Agreement (No Bill) -Section 122 Balance of Payment Tariffs -Section 301 Excess Capacity/Forced Labor Investigations -Medical Devices/PPE Section 232 Inve
Follow PG- Became public
- Jul 22, 2026, 12:04 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 10, 2026, 5:30 PM EST
Why this is connected
Legal-name match: THE PROCTER AND GAMBLE COMPANY is PROCTER & GAMBLE Co (https://www.sec.gov/Archives/edgar/data/80424/), differing only in punctuation, "the" or suffix spelling (Corp/Corporation).
Reported lobbying amounts
Expenses: $661,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/bdd55bc4-96a6-44e2-bd25-ffc3fb3ed860/","filing_uuid":"bdd55bc4-96a6-44e2-bd25-ffc3fb3ed860","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/bdd55bc4-96a6-44e2-bd25-ffc3fb3ed860/print/","filing_document_content_type":"text/html","income":null,"expenses":"661000.00","expenses_method":"C","expenses_method_display":"C","posted_by_name":"Robert Cusmano","dt_posted":"2026-07-22T12:04:37-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"701 PENNSYLVANIA AVENUE, NW, #520","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":32225,"url":"https://lda.gov/api/v1/registrants/32225/","house_registrant_id":31703,"name":"THE PROCTER AND GAMBLE COMPANY","description":"Manufacturing","address_1":"701 PENNSYLVANIA AVENUE, NW, #520","address_2":null,"address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ROBERT CUSMANO","contact_telephone":"+1 202-393-3400","dt_updated":"2026-07-31T10:30:47.581131-04:00"},"client":{"id":140464,"url":"https://lda.gov/api/v1/clients/140464/","client_id":24,"name":"THE PROCTER AND GAMBLE COMPANY","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2013-10-09"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"-Issues related to FDA review of active ingredients in over-the-counter products","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142463,"prefix":null,"prefix_display":null,"first_name":"CHRISTINA","nickname":null,"middle_name":null,"last_name":"LOTSPIKE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":11,"name":"Executive Office of the President (EOP)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"-Issues related to Generally Recognized as Safe (GRAS) and Additive Ingredients Regulation -H.R. 1219, Oral Health Products Inclusion Act -Issues related to New Approach Methodologies (NAMs) non-animal technologies used to evaluate drug safety and efficacy","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142463,"prefix":null,"prefix_display":null,"first_name":"CHRISTINA","nickname":null,"middle_name":null,"last_name":"LOTSPIKE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"-Section 232 Steel/Aluminum Trade Investigation -Issues Related to the Review of the US-Mexico-Canada Trade Agreement (No Bill) -Section 122 Balance of Payment Tariffs -Section 301 Excess Capacity/Forced Labor Investigations -Medical Devices/PPE Section 232 Investigation -U.S.-China Board of Trade -Industrial Machinery Section 232 Investigation -Issues related to counterfeit products/illicit trade","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142463,"prefix":null,"prefix_display":null,"first_name":"CHRISTINA","nickname":null,"middle_name":null,"last_name":"LOTSPIKE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57330,"prefix":"mrs","prefix_display":"MRS.","first_name":"TARA","nickname":null,"middle_name":"HOGAN","last_name":"CHARLES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":90997,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":null,"last_name":"CUSMANO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":121817,"prefix":null,"prefix_display":null,"first_name":"NICOLE","nickname":null,"middle_name":"C","last_name":"COLLIER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":11,"name":"Executive Office of the President (EOP)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CSP","general_issue_code_display":"Consumer Issues/Safety/Products","description":"-Issues Related to Product Safety and Quality Assurance (No Bill) -Issues related to Labeling of Menstrual Products -PACK Act (Packaging and Claims Knowledge Act) HR 6832","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142463,"prefix":null,"prefix_display":null,"first_name":"CHRISTINA","nickname":null,"middle_name":null,"last_name":"LOTSPIKE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152267,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"DAVID","last_name":"BISENIUS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57330,"prefix":"mrs","prefix_display":"MRS.","first_name":"TARA","nickname":null,"middle_name":"HOGAN","last_name":"CHARLES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145129,"prefix":null,"prefix_display":null,"first_name":"JULIA","nickname":null,"middle_name":null,"last_name":"HENSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":121817,"prefix":null,"prefix_display":null,"first_name":"NICOLE","nickname":null,"middle_name":"C","last_name":"COLLIER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":46,"name":"Consumer Product Safety Commission (CPSC)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CHM","general_issue_code_display":"Chemicals/Chemical Industry","description":"-Implementation of Cybersecurity Reporting Law -Issues related to Toxic Substances Control Act Reform -Safer Choice Program Authorization Act (S. 4664)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145129,"prefix":null,"prefix_display":null,"first_name":"JULIA","nickname":null,"middle_name":null,"last_name":"HENSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152267,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"DAVID","last_name":"BISENIUS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":90997,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":null,"last_name":"CUSMANO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":121817,"prefix":null,"prefix_display":null,"first_name":"NICOLE","nickname":null,"middle_name":"C","last_name":"COLLIER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"ENV","general_issue_code_display":"Environment/Superfund","description":"-H.R. 2269/S. 1092 - Wastewater Infrastructure Pollution Prevention and Environmental Safety (WIPPES) Act -Recycled Materials Attribution Act (RMAA) HR 7502 -Issues related to sustainability","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152267,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"DAVID","last_name":"BISENIUS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":90997,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":null,"last_name":"CUSMANO","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"-OECD Digital Tax Project (Global Minimum Tax Implementation) -Implementation of H.R. 1 - One Big Beautiful Bill Act (Corporate/International Provisions) -OECD Digital Tax Project (Reallocation of Global Taxing Rights) -Ongoing Negotiations of US Bilateral Tax Treaties -Oral Health Products Inclusion Act (H.R. 1219)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":90997,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":null,"last_name":"CUSMANO","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRU","general_issue_code_display":"Trucking/Shipping","description":"-Issues related to the SHIP IT Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142463,"prefix":null,"prefix_display":null,"first_name":"CHRISTINA","nickname":null,"middle_name":null,"last_name":"LOTSPIKE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Price change after we could observe it
+0.21% PG
Adjusted closing prices from Nov 11, 2026 to Nov 12, 2026. SPY changed -0.35% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.
Congressional trading in PG
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 5, 2026$1K–$15K
Rep. Maria Elvira Salazar (R-FL-27)
Bought The Procter & Gamble Company PG
$1K–$15K · Traded Oct 23, 2026 · disclosed Nov 5, 2026
- Nov 5, 2026$1K–$15K
Rep. Maria Elvira Salazar (R-FL-27)
Bought The Procter & Gamble Company PG
$1K–$15K · Traded Oct 23, 2026 · disclosed Nov 5, 2026
- Oct 27, 2026$1K–$15K
Rep. Pete Sessions (R-TX-17)
Sold The Procter & Gamble Company PG
$1K–$15K · Traded Oct 8, 2026 · disclosed Oct 27, 2026
Traded 14 days before earnings - Oct 15, 2026$1K–$15K
Rep. David J. Taylor (R-OH-2)
Sold The Procter & Gamble Company PG
$1K–$15K · Traded Oct 12, 2026 · disclosed Oct 15, 2026
Traded 10 days before earnings - Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought The Procter & Gamble Company PG
$1K–$15K · Traded Sep 25, 2026 · disclosed Oct 7, 2026 · Spouse
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought The Procter & Gamble Company PG
$1K–$15K · Traded Sep 11, 2026 · disclosed Oct 7, 2026 · Dependent
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Sold The Procter & Gamble Company PG
$1K–$15K · Traded Sep 2, 2026 · disclosed Oct 7, 2026 · Dependent
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Sold The Procter & Gamble Company PG
$1K–$15K · Traded Sep 2, 2026 · disclosed Oct 7, 2026 · Spouse
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.